Denise M. Wolf, MD, PhD, University of California, San Fransisco, CA, highlights the limitations of current biomarker assessments in breast cancer treatment and emphasizes the importance of incorporating immune predictors for better treatment outcomes. Traditionally, treatment decisions have been based on hormone receptor and HER2 status, but with the expanding range of treatment options, additional biology, particularly immune predictors, are needed. Understanding the probability of response to immunotherapy becomes crucial, especially in triple-negative breast cancer with potential autoimmune issues. The evolving landscape may bring multiple immune biomarkers, and improving response prediction will be key to providing personalized and effective breast cancer treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.